Journal article
Stroke Outcomes in the COMPASS Trial
Abstract
BACKGROUND: Strokes were significantly reduced by the combination of rivaroxaban plus aspirin in comparison with aspirin in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies). We present detailed analyses of stroke by type, predictors, and antithrombotic effects in key subgroups.
METHODS: Participants had stable coronary artery or peripheral artery disease and were randomly assigned to receive aspirin 100 mg …
Authors
Sharma M; Hart RG; Connolly SJ; Bosch J; Shestakovska O; Ng KKH; Catanese L; Keltai K; Aboyans V; Alings M
Journal
Circulation, Vol. 139, No. 9, pp. 1134–1145
Publisher
Wolters Kluwer
Publication Date
February 26, 2019
DOI
10.1161/circulationaha.118.035864
ISSN
0009-7322